PMID- 10629409
OWN - NLM
STAT- MEDLINE
DCOM- 20000225
LR  - 20171101
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 29 Suppl S1
DP  - 1999 Dec
TI  - Direct thrombin inhibitors.
PG  - 76-8
AB  - Direct thrombin inhibitors may offer advantages over indirect thrombin inhibitors 
      in the management of patients with acute coronary syndromes (ACS). Two direct 
      thrombin inhibitors, hirudin and bivalirudin, have been investigated in Phase II 
      and Phase III clinical trials. Based on the results of a meta-analysis of study 
      data from 25,000 patients, hirudin appears to be more effective than 
      unfractionated heparin (UFH) in the treatment of patients with ACS, but it is 
      associated with an increased rate of major bleeding. A meta-analysis of a smaller 
      patient population has suggested that bivalirudin, too, may be more efficacious 
      than UFH and may also be safer.
CI  - Copyright 1999 S. Karger AG, Basel
FAU - Anand, S
AU  - Anand S
AD  - McMaster University, Hamilton General Hospital, Hamilton, Ont., Canada.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Animals
MH  - *Antithrombins/pharmacology/therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Hirudin Therapy
MH  - Hirudins/analogs & derivatives/pharmacology
MH  - Humans
MH  - Peptide Fragments/pharmacology/therapeutic use
MH  - Recombinant Proteins/pharmacology/therapeutic use
EDAT- 2000/01/12 09:00
MHDA- 2000/03/04 09:00
CRDT- 2000/01/12 09:00
PHST- 2000/01/12 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/01/12 09:00 [entrez]
AID - 54117 [pii]
AID - 10.1159/000054117 [doi]
PST - ppublish
SO  - Haemostasis. 1999 Dec;29 Suppl S1:76-8. doi: 10.1159/000054117.